Ximelagatran (Exanta): Alternative to Warfarin?(Pharmacology Notes) (Drug Overview) Ximelagatran (Exanta): Alternative to Warfarin?(Pharmacology Notes) (Drug Overview)

Ximelagatran (Exanta): Alternative to Warfarin?(Pharmacology Notes) (Drug Overview‪)‬

Baylor University Medical Center Proceedings 2005, Jan, 18, 1

    • £2.99
    • £2.99

Publisher Description

For decades, the standards of antithrombotic therapy have been heparin and coumarin compounds, primarily warfarin (1). Other newer approaches include low-molecular-weight heparins, fondaparinux, lepirudin, argatroban, and melagatran (investigational). Although existing treatments are effective, they have many limitations. A safer, more convenient therapy is needed. Ximelagatran is the first oral treatment in a new World Health Organization class of direct thrombin inhibitors and is the first new oral anticoagulant since the introduction of warfarin almost 60 years ago (2). It was submitted to the Food and Drug Administration (FDA) for approval in December 2003 (3). Each year, nearly 4 million people worldwide experience a primary thrombotic event, and those at greatest risk include people with atrial fibrillation, those who have experienced a previous cardiac event such as a myocardial infarction, and patients who have recently undergone orthopaedic surgery, such as total hip or knee replacement surgery (4). Current mainstays of therapy for preventing or treating thrombosis are not ideal. Warfarin, although available in an oral form, has a slow onset of action, interacts with numerous foods and drugs, and requires intensive monitoring of coagulation with frequent dose adjustments. Heparins, fondaparinux, lepirudin, argatroban, and melagatran (investigational) are limited by their route of administration, especially in an outpatient setting, as all are administered parenterally (5, 6). Ximelagatran, a prodrug of melagatran, is an orally administered direct inhibitor of both free and clot-bound thrombin. It is rapidly absorbed and quickly converted to its active form, melagatran, with stable and reproducible pharmacokinetic properties. No clinically significant interactions with food or cytochrome P450-metabolized drugs have been reported for ximelagatran, and the drug requires no monitoring (7).

GENRE
Health & Well-Being
RELEASED
2005
1 January
LANGUAGE
EN
English
LENGTH
17
Pages
PUBLISHER
The Baylor University Medical Center
SIZE
230.2
KB

More Books Like This

Low Molecular Weight Heparins in Patients with Renal Insufficiency (Pharmacy News and Reviews) Low Molecular Weight Heparins in Patients with Renal Insufficiency (Pharmacy News and Reviews)
2008
Therapeutic Drug Monitoring Data Therapeutic Drug Monitoring Data
2019
New Agents and Strategies in the Management of Multiple Myeloma: 2014 New Agents and Strategies in the Management of Multiple Myeloma: 2014
2014
Standards of Laboratory Practice: Analgesic Drug Monitoring (Nacb Symposium) Standards of Laboratory Practice: Analgesic Drug Monitoring (Nacb Symposium)
1998
Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring
2012
Phytopharmacy Phytopharmacy
2015

More Books by Baylor University Medical Center Proceedings

Sarcoidosis: Still a Mystery?(Disease/Disorder Overview) Sarcoidosis: Still a Mystery?(Disease/Disorder Overview)
2001
Acute Postoperative Pain Management. Acute Postoperative Pain Management.
2000
Biological Warfare and Bioterrorism: A Historical Review. Biological Warfare and Bioterrorism: A Historical Review.
2004
Tennis Elbow (Disease/Disorder Overview) Tennis Elbow (Disease/Disorder Overview)
2008
Sports Hernia: The Experience of Baylor University Medical Center at Dallas (Clinical Report) Sports Hernia: The Experience of Baylor University Medical Center at Dallas (Clinical Report)
2011
Facts and Ideas from Anywhere (Advice of Sir William Osler, Bart. On Practicing Medicine) (Norman J. Holter, The Inventor of Hotler Electrocardiogram) (Great Benefits of Running) (Editorial) (Reprint) (Biography) Facts and Ideas from Anywhere (Advice of Sir William Osler, Bart. On Practicing Medicine) (Norman J. Holter, The Inventor of Hotler Electrocardiogram) (Great Benefits of Running) (Editorial) (Reprint) (Biography)
2006